| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID |
|
| ChemSpider |
|
| UNII |
|
| CompTox Dashboard(EPA) |
|
| Chemical and physical data | |
| Formula | C20H29N3O2 |
| Molar mass | 343.471 g·mol−1 |
| 3D model (JSmol) |
|
| |
| |
ADBICA (also known asADB-PICA) is adesigner drug identified insynthetic cannabis blends in Japan in 2013.[1] ADBICA had not previously been reported in the scientific literature prior to its sale as a component of synthetic cannabis blends. ADBICA features a carboxamide group at the 3-indole position, likeSDB-001 andSTS-135. The stereochemistry of the tert-butyl side-chain in the product is unresolved, though in a large series of indazole derivatives structurally similar to ADBICA that are disclosed in Pfizer patent WO 2009/106980, activity resides exclusively in the (S) enantiomers.[2] ADBICA is a potentagonist of theCB1 receptor andCB2 receptor with an EC50 value of 0.69 nM and 1.8 nM respectively.[3]
As of October 2015 ADBICA is a controlled substance in China.[4]
Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |